Biotech was easily the top performer as August drew to a close.
You can see how the performance of the SPDR S&P Biotech ETF (XBI) outperformed the pack in the chart below.
In the next chart, we can see that a top performing stock in the biotech sector is Bluebird Bio (BLUE), a direct peer of Kite Pharma.
Gilead got a bump as well, but the big question for investors is whether new revenue from the Kite acquisition will offset the sales decline the company is experiencing with its Hep C class of drugs.
Gilead has said it doesn’t expect the Kite acquisition to be accretive to earnings for three years.
According to the Wall Street Journal, Kite’s immunotherapy treatment is expected to produce revenue of only $1.7 billion worldwide by 2022.
It is worth thinking about how the market is viewing the recent acquisition and Gilead’s surge.
Is it because the market perceives that the acquisition will spark Gilead’s revenue growth?
Or do investors see Gilead as cheap, with its stock price trading at only 11 times 2018 earnings?
In my opinion, it would seem from the estimates that the acquisition is unlikely to add meaningful revenue or EPS in the near-term to warrant a sharp increase in the stocks price.
Regardless, I think the biotech sector is getting a much-needed spark, something that’s been missing for well over two years now.
How long it will last is anyone’s guess, but I have been increasingly more bullish on the sector for some time.
- Mott Capital Management uses a long-term thematic growth approach to investing in equities. We search for investments that both reflect and help to shape generational and demographic shifts. Mott uses a philosophy of buying these companies for a 3- to 5-year time horizon, with the belief that a long-term holding period gives themes and our chosen companies a chance to fully develop. In our view, the long time horizon also serves to mitigate the risk associated with the short-term impact of market volatility.